Analysed BIOMEA FUSION INC (BMEA:NASDAQ) News Sources
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
05-05-2026
yahoo.com
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
11-05-2026
yahoo.com
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
03-06-2026
yahoo.com
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
05-06-2026
yahoo.com
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
05-08-2026
yahoo.com
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
13-08-2026
yahoo.com
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
24-08-2026
yahoo.com
What is the current price of BIOMEA FUSION INC (BMEA:NASDAQ)?
The current price of BIOMEA FUSION INC (BMEA:NASDAQ) is $1.74.
BIOMEA FUSION INC (BMEA:NASDAQ) absolute price change since previous trading day?
The absolute price change of BIOMEA FUSION INC (BMEA:NASDAQ) since the previous trading day is $0.04.
BIOMEA FUSION INC (BMEA:NASDAQ) percentage price change since previous trading day?
The percentage price change of BIOMEA FUSION INC (BMEA:NASDAQ) since the previous trading day is 2.3529%.
What is the most recent average sentiment score for BIOMEA FUSION INC (BMEA:NASDAQ)?
The most recent average sentiment score for BIOMEA FUSION INC (BMEA:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for BIOMEA FUSION INC (BMEA:NASDAQ)?
The most recent sentiment for BIOMEA FUSION INC (BMEA:NASDAQ) is .
SEC-8K** Filing Available For BIOMEA FUSION INC (BMEA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.